The choice of optimal drug therapy in patients with atrial fibrillation and comorbid pathology.

Authors

DOI:

https://doi.org/10.26641/1997-9665.2018.4.104-115

Keywords:

arterial hypertension, atrial fibrillation, coronary artery disease, treatment

Abstract

Background. Nowadays, atrial fibrillation is considered as a potentially fatal arrhythmia, because of the wide range of its negative outcomes associated not only with a significant deterioration in the patient’s life quality, but also with a significant increase in the rate of fatal complications. Objective. The aim of the work was to determine the effectiveness of drug treatment in patients with persistent atrial fibrillation, hypertension and ischemical heart disease. Methods. The study included 42 patients (mean age - 63.5 ± 2.3; men - 21 (50 %)), with persistent atrial fibrillation, arterial hypertension and chronic ischemic heart disease (stable angina pectoris, classes II-III). All patients had arterial hypertension II-III degree. Patients were divided into groups comparable by age, sex and clinical characteristics. Rivaroxaban 20 mg per day or warfarin (under the control of international normalized ratio), losartan 50-100 mg per day, bisoprolol 5-10 mg per day and atorvastatin - 40 mg per day were administrared to the patient of the main group (n = 21). Nitric oxide donor («Tivortini» 100 ml intravenously) was prescribed in addition to complex therapy. Rivaroxaban at a dose of 20 mg per day or warfarin (under the control of international normalized ratio), ramipril 5-10 mg per day, bisoprolol 5-10 mg per day and atorvastatin - 20 mg per day were administrared to the patient of the control group (n = 21). Results. The use of losartan and ramipril showed the equal antihypertensive effect in patients with atrial fibrillation, ischemic heart disease, and arterial hypertension, which was determined by a significant decrease of systolic and diastolic blood pressure. 19 (90.47 %) patients of losartan group and 17 (80.95 %) - of ramipril one reached the target level of the blood pressure (BP < 140 and 90 mm. hg). A significant improvement in glomerular filtration rate indices and a decrease in uric acid levels were determined in patients treated with losantan. Conclusion. Combination therapy in patients with persistent atrial fibrillation, arterial hypertension and ischemic heart disease consisting of losartan, high doses of atorvastatin and nitric oxide donor contributed to control of the blood pressure, reducing the number and duration of angina attacks, exercise tolerance improving, and also led to a significant decrease in a total cholesterol level, low - density lipoprotein - cholesterol, triglycerides, atherogenic index and uric acid levels.

References

  1. Tashchuk VK, Denysiuk VI, Hrebtii HI. [Pathogenetic reatures of hypertension treatment in patients with concomitant abdominal obesity and underweight]. Buk. Med. Herald. 2014;18(2):105-8. Ukrainian.
  2. Lloyd-Jones DM, Wang TJ, Leip EP, et all. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;31(9):105-8. doi:10.1161/01.CIR.0000140263.20897.42.
  3. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-7. doi:10.1016/j.amjcard.2013.05.063.
  4. Thomas MC, Dublin S, Kaplan RC, et all. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21(10):1111–6. doi: 10.1038/ajh.2008.248. PMID: 18756257
  5. Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension. 2012;59(2):198-204. doi:10.1161/HYPERTENSIONAHA.111.179713.
  6. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119(16):2146-52. doi:10.1161/ CIRCULATIONAHA.108. 830042. PMID:19364977
  7. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D'Agostino RB Sr, Kannel WB, Levy D, Benjamin EJ. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;21(7):709-15. doi:10.1001/jama.297.7.709.
  8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. PMID:12493255
  9. Kistler PM1, Sanders P, Dodic M, Spence SJ, Samuel CS, Zhao C, Charles JA, Edwards GA, Kalman JM. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J. 2006;27(24):3045-56. DOI:10.1093 /eurheartj/ehl360. PMID:17098760
  10. Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC; RACE Investigators. Enhanced cardiovascular morbidity and mortality durind rhythm control treatment in persistant atrial fibrillation in hypertensives: data of the RACE study. Eur Heart J. 2007;28(6):741-51. doi:10.1093/eurheartj/ehl436.
  11. Baranova EI. [Atrial fibrillation and arterial hypertension]. Arterial’naja gipertenzija. 2011;17(4): 293-304. Russian.
  12. Sychov OS, Shabilyanova LA, Lizogub SV, Mogilnitskii YeV, Lobko OA. [The efficacy of antiarrhythmic therapy in patients with paroxysmal and persistent atrial fibrillation depending on the type of paroxysms]. Ukrainian journal of cardiology. 2013;2:66-9. Ukrainian.
  13. Korost YaV, Bula LS, Suprunyuk VP. [Atministration delails of ARB II in a treatment of cardiovascular disease]. Liky` Ukrayiny`. 2014;1:19-24. Ukrainian.
  14. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Xu J, Liu TS, Yang JJ, Reudelhuber TL, Yang XP. Local angionensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol. 2010;299(5):H1328-38. doi:10.1152/ajpheart.00538.2010.
  15. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cadiac cell proliferation and intramiocardial perivascular fibrosis. Circulation. 1998;98(24):2765-73. PMID:9851965
  16. Kannel WB, Benjamin EJ. Final draft status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–ix. doi: 10.1016/j.mcna.2007.09.002. PMID: 18060995.
  17. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S. Expression of angiotensin II receprors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol. 2003;42(10):1785-92. PMID:14642689
  18. Solovyan AN. [Structural and functional condition of the myocardium, heart rate variability and cardiac electrophysiological properties in different neuroautonomic types of paroxysmal atrial fibrillatin]. Ukrayins`ky`j kardiologichny`j zhurnal. 2015;3(15):38-47. Ukrainian.
  19. [Order of HM of Ukraine dated 15.06.2016 N 597. On approval and implementation of medical-technological documents on standardization of medical care at atrial fibrillation]. Kyiv; 2016. Ukrainian.
  20. Koval EA. [Possibilities of medical correction in patients of high thromboembolic risk who were undergoing in-patient treatment]. Serce i sudy`ny`. 2013;1(41):94–9. Ukrainian.
  21. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26(3):403-11. doi:10.1097/HJH.0b013e3282f35c67.
  22. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152(1):86-92. PMID:16838426.
  23. Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med. 2010;152(2):78-84. doi:10.7326/0003-4819-152-2-201001190-00005.

Downloads

How to Cite

Yalovenko, M. I., & Khaniukov, O. O. (2018). The choice of optimal drug therapy in patients with atrial fibrillation and comorbid pathology. Морфологія / Morphologia / Morfologìâ, 12(4), 104–115. https://doi.org/10.26641/1997-9665.2018.4.104-115

Issue

Vol. 12 No. 4 (2018)

Section

Статті

License

Copyright (c) 2018 Yalovenko M.I., Khaniukov O.O., Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.